Tiziana Life Sciences (NASDAQ:TLSA) Stock Rating Raised to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Tiziana Life Sciences (NASDAQ:TLSA) from a strong sell rating to a sell rating in a report issued on Saturday morning,Wall Street Zen reports.

Several other research firms also recently weighed in on TLSA. Zacks Research raised shares of Tiziana Life Sciences to a “hold” rating in a research report on Tuesday, July 14th. Weiss Ratings upgraded shares of Tiziana Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, October 19th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Tiziana Life Sciences in a research report on Tuesday, September 22nd. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Tiziana Life Sciences presently has an average rating of “Hold”.

Tiziana Life Sciences Stock Down 5.0%

TLSA opened at $0.95 on Friday. The firm’s fifty day moving average price is $1.03 and its 200 day moving average price is $1.15. Tiziana Life Sciences has a 12-month low of $0.76 and a 12-month high of $2.10.

Insider Activity

In other Tiziana Life Sciences news, CEO Ivor Elrifi purchased 667,000 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was acquired at an average cost of $1.00 per share, with a total value of $667,000.00. Following the acquisition, the chief executive officer owned 4,472,261 shares of the company’s stock, valued at approximately $4,472,261. This represents a 17.53% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. In the last 90 days, insiders have bought 988,423 shares of company stock valued at $985,909. Company insiders own 39.82% of the company’s stock.

Institutional Investors Weigh In On Tiziana Life Sciences

An institutional investor recently raised its position in Tiziana Life Sciences stock. Mid American Wealth Advisory Group Inc. boosted its holdings in Tiziana Life Sciences Ltd (NASDAQ:TLSA) by 38.8% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 448,667 shares of the company’s stock after acquiring an additional 125,427 shares during the period. Mid American Wealth Advisory Group Inc. owned about 0.35% of Tiziana Life Sciences worth $498,000 at the end of the most recent quarter.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biotechnology company developing therapies that modulate the immune system to treat neuroinflammatory and neurodegenerative diseases. The company’s lead product candidate is foralumab, a fully human monoclonal antibody designed to target the CD3 receptor on T cells and potentially reduce harmful immune activation.

Tiziana is primarily evaluating an intranasal formulation of foralumab in conditions involving inflammation of the central nervous system, including non-active secondary progressive multiple sclerosis and Alzheimer’s disease.